18 results about "Haemoglobin Suresnes" patented technology

A system (100) and method (1000) for managing fluid administration to a patient (120) following administration of an anaesthetic. The system (100) comprises a processor (112) configured to receive monitored patient haemoglobin data before and after the administration of the anaesthetic. The processor (112) is configured to calculate a baseline blood volume (BBV) of the patient (120). After administration of the anaesthetic, the processor (112) is configured to calculate a target blood volume (TBV), wherein the target blood volume (TBV) is calculated by comparing the monitored patient haemoglobin data before and after the administration of the anaesthetic.

The present invention provides a method for determining a mortality risk and / or probability of healthy lifespan of a cat; said method comprising determining the level of one or more biomarker(s) in one or more samples obtained from the cat, wherein the one or more biomarker(s) is selected from white blood cell count, haemoglobin, serum urea nitrogen, serum AST, serum chloride, serum total bilirubin, serum globulin, red blood cell count, serum sodium, serum cholesterol, serum potassium, serum alkaline phosphatase, and / or serum GGT.

The present invention relates to a method for determining a mortality risk and / or probability of a healthy lifespan of a dog; said method comprising determining the level of one or more biomarker(s) in one or more samples obtained from the dog, wherein the one or more biomarker(s) is selected from white blood cell count, serum albumin, serum alkaline phosphatase, serum creatine kinase, haemoglobin, haematocrit, mean corpuscular haemoglobin, serum glucose, mean red cell volume, serum globulin, serum calcium, platelet count, and / or red blood cell count.

The present disclosure relates to a staining reagent combination comprising a reagent A and a reagent B. The staining reagent combination is capable of simultaneously assessing total count of WBC, differential count of WBC and haemoglobin concentration from a biological sample in suspension form. The staining reagent combination is ideal for use in microfluidic platforms due to its high viscosity and lower volume required for measurement. The staining reagent combination is economical, non-toxic, has quick reaction and long working time.

A method of monitoring an analyte in blood, particularly glycated-haemoglobin (HbA1c or HgbA1c) using two photoplethysmocharty (PPG) sensors, which are worn on the body of a subject. Each photoplethysmocharty sensor observes blood of the subject in a different wavelength. One of the wavelengths monitors glycated-haemoglobin. The other one of the wavelengths monitors the body of blood in general. The shapes of the pulses obtained by each of the PPG sensor from the subject are used to adjust the intensity of the light emitted by the PPG sensors into the subject. If on adjustment of the light intensity, the shapes of the pulses become similar, the size of the pulses can be used to provide quasi-quantification of the analyte.

The present disclosure provides in vitro methods for identifying the presence or absence of haemoglobin S (HbS) or haemoglobin C (HbC) in a blood sample, kits and devices thereof. The inventors have found that HbS shows a substantial decrease in absorption under deoxygenated conditions compared to oxygenated conditions. The inventors expect HbC to show a similar decrease in absorption under deoxygenated conditions compared to oxygenated conditions. The methods, kits and devices of the disclosure employ this decrease in absorption under deoxygenated conditions to identify the presence or absence of HbS or HbC in a blood sample. The methods, kits and devices of the present disclosure are simple, low cost, and provide a rapid way to identify the presence or absence of HbS or HbC in a blood sample in a point-of-care setting.

A method of assessing risk of mortality of a cancer patient comprising inputting cancer patient information to a model to generate a score indicative of risk of mortality of the cancer patient, wherein the patient information includes data corresponding to one or more cancer type-specific parameters, and data corresponding to each of the following parameters: level of albumin in serum or plasma, Eastern cooperative oncology group (ECOG) performance status, ratio of lymphocytes to leukocytes in blood, smoking status, age, TNM classification of malignant tumours stage, heart rate, chloride or sodium level in serum or plasma, urea nitrogen level in serum or plasma, gender, haemoglobin or haematocrit level in blood, aspartate aminotransferase enzymatic activity level in serum or plasma, and alanine aminotransferase enzymatic activity level in serum or plasma.

The purpose of the present invention is to provide a medicine that is for use in instances of cyanide poisoning, hydrogen sulfide poisoning, and azide poisoning, that does not cause side effects, and that has excellent quick-acting properties and a high antidote effect. Specifically, the present invention is a medicine that is for use in instances of cyanide poisoning, hydrogen sulfide poisoning, and azide poisoning, and that contains, as an active ingredient, at least one selected from the group consisting of hemeproteins capable of binding to a cyanide ion (CN-), a hydrogen sulfide ion (HS-), and an azide ion (N3 -), hemeprotein-containing substances capable of binding to CN-, HS-, and N3 -, and heme derivatives capable of binding to CN-, HS-, and N3. More specifically, the present invention is a medicine or pharmaceutical composition for treatment or prophylaxis of cyanide poisoning, hydrogen sulfide poisoning, and azide poisoning.

The present invention relates to daprodustat or a pharmaceutically acceptable salt thereof for use in reducing fatigue in non-dialysis subjects with anemia associated with chronic kidney disease. In particular embodiments, the invention is directed to particular subject populations in which the subject has hsCRP≥6.60 mg / L at baseline and in which the subject has a haemoglobin concentration of ≤11 g / dL at baseline.

The invention relates to the field of medicine and veterinary medicine, in particular to a new use of the poloxamer as a pharmacologically active substance A new use of the poloxamer as a pharmacologically active substance to increase the levels of haemoglobin and red blood cells in a patients blood is revealed. Thus, new pharmacologically active substances that promote a rise in haemoglobin and red blood cell levels in a patients blood were found, the use of which ensures the achievement of the technical result consisting in a significant reduction of the toxic effect and side effects of these substances on the patients body in the case of oral and parenteral administration.

The present invention relates to an expression system for producing a recombinant haptoglobin (Hp) beta chain, or a haemoglobin-binding fragment thereof, recombinant Hp molecules and uses thereof for treating and / or preventing a condition associated with cell-free haemoglobin (Hb).

A method of determining the concentration of oxyhaemoglobin HbO2 and deoxyhaemoglobin Hb in an imaged tissue. The method comprises receiving a measured attenuation spectrum comprising n light attenuation measurement sets of the imaged tissue. Each light attenuation measurement set is at a different one of n wavelength bands. Each light attenuation measurement set comprises a plurality of light attenuation measurements, one for each pixel or group of pixels in the image of the tissue. The received measured attenuation spectrum is fit to a model attenuation spectrum which comprises a linear combination of a haemoglobin spectrum and a linear background spectrum. A set of n simultaneous equations are solved, each equating a light attenuation measurement set to the model attenuation spectrum for the wavelength band of the light attenuation measurement set. Solving comprises determining values of the concentration of oxyhaemoglobin HbO2 and deoxyhaemoglobin Hb and background coefficients which causes the measured attenuation spectrum to best fit the model attenuation spectrum.

The present invention relates to a system for detecting diseases and providing healthcare services (100). The system (100) comprises of a plurality of handheld devices (102), a database (126) for storing data of patient and a software module (128). The handheld device (102) is configured to measure vital parameter of a patient's body through a plurality of sensors (110), wherein the plurality of sensor (110) includes a temperature sensor (112), a pulse oximeter sensor (114), a pulse sensor (116), a plurality of ECG leads (118), a blood pressure sensor (120). Additionally, the handheld device (102) may be interfaced to the glucometer and haemoglobin meter. The handheld device (102) is further configured to connect the user to a healthcare provider for consultation through a video call. Therefore, the present invention bridge the gap between rural patients and experienced medical professionals, thereby improving healthcare access for those in remote or underserved areas.

The invention relates to substituted pyridine derivatives that are inhibitors of the activity of DNA methyltransferase 1 (DNMT1). The invention also relates to pharmaceutical compositions comprising such compounds and methods of using such compounds in the treatment of cancer, pre-cancerous syndromes, beta haemoglobinopathy disorders, and other diseases associated with inappropriate DNMT1 activity.

The present disclosure relates generally to methods of treating or preventing an adverse secondary neurological outcome in a subject following a haemorrhagic stroke accompanied by extravascular erythrolysis and release of cell-free heme and / or cell-free haemoglobin (Hb) into a cerebral spinal fluid (CSF), the method comprising exposing the CSF of a subject in need thereof to a therapeutically effective amount of hemopexin (Hx) and for a period of time sufficient to allow the Hx to form a complex with, and thereby neutralise, the cell-free heme and, optionally, exposing the CSF of the subject to a therapeutically effective amount of haptoglobin (Hp) and for a period of time sufficient to allow the Hp to form a complex with, and thereby neutralise, the cell-free Hb.

The present disclosure provides methods for determining optical absorbance of a blood sample, methods for identifying the presence or absence of sickle haemoglobin in a blood sample, kits and devices thereof The present methods comprise measuring a first absorbance of the blood sample under a deoxygenated condition at 420-440 nm and measuring a second absorbance of the blood sample under the deoxygenated condition at 541-570 nm. A ratio of the second absorbance to the first absorbance and a difference between the first absorbance and the second absorbance are calculated and employed to identify the presence or absence of sickle haemoglobin and determine the amount of sickle haemoglobin. The methods, kits and devices of the present disclosure are simple, low cost, and provide a rapid way to identify the presence or absence of and amount of sickle haemoglobin in a blood sample in a point-of-care setting.

The present invention relates to a method to determine the concentration of sickle-cell haemoglobin in blood. Said method is based on a smear technique involving drawing a smear at a particular speed, wherein the length of the smear is a function of the concentration of the HbS. It also provides a smear card having graduations to measure the smear length and the corresponding viscosity (in cP) and a device comprising such smear card; reducing agent and substrate.